SCA
PGNX

Secor Capital Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Secor Capital Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-27,580
Closed -$120K – 765
2016
Q1 		$120K Buy
+27,580
New +$123K 0.02% 575

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Secor Capital Advisors's PGNX Position: Q2 2016 in Review

Secor Capital Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2016, closing a stake of 27,580 shares — an estimated $120K sold.

Secor Capital Advisors first reported a position in PGNX in Q1 2016 and held it in 1 quarter. The position peaked at $120K in Q1 2016. 104 funds tracked by Wall St. Rank hold PGNX as of Q2 2016.

  • Secor Capital Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • Secor Capital Advisors sold 27,580 Progenics Pharmaceuticals Inc shares in Q2 2016, an estimated $120K.
  • Secor Capital Advisors first reported a position in Progenics Pharmaceuticals Inc in Q1 2016 and held it in 1 quarter.
  • Secor Capital Advisors's Progenics Pharmaceuticals Inc position peaked at $120K in Q1 2016.
  • 104 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2016.

Based on Secor Capital Advisors's 13F filing for Q2 2016, filed 9 Aug 2016.